Eikon Therapeutics Inc.

10/23/2026 | Press release | Distributed by Public on 10/23/2026 09:00

A first-in-human Phase 1/2 study of EIK1004, a PARP1-selective CNS-penetrant inhibitor, in patients with advanced solid tumors with HRR mutations

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.
Eikon Therapeutics Inc. published this content on October 23, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 23, 2026 at 15:00 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]